Simoa® digital immunoassay technology is transforming the study of neurology, infectious disease, oncology, and other research areas by enabling researchers to examine critical proteins at ultra-low – even baseline – levels, in most non-invasive sample types. Simoa allows researchers to expand the limits of biomarker research by measuring single or multiplex targets at femtogram levels in record time.
Throughout the many stages of drug discovery, various imaging techniques play an important role in identifying drug targets, testing candidate efficacy, and the drug’s biodistribution and pharmacokinetics.
Imaging techniques allow non-invasive visualization, characterization, and quantification of biological events within organisms in response to drugs. These techniques make use of the properties of probes or the tissue itself and are important for disease research and drug discoveries.
Imaging relies on developing agents that are selectively taken up or retained by the biological process of interest. And this agent generates a signal that can be visualized by radiography, ultrasound, magnetic resonance, and optical (bioluminescence or fluorescence) imaging.
Drug discovery in the pharmaceutical industry is hindered by the huge costs involved in searching for new therapeutics. It is estimated that a new drug costs an average of $2.6 billion to develop, with much of that money wasted on researching candidate drugs that fail to get approved past phase I trials.
Virtual screening (VS) is a computational technique that is being implemented by pharmaceutical companies to improve their research and design phase. VS automatically searches through libraries of molecules and selects those that have structures considered to be most likely to effectively bind to a therapeutic target, such as a protein receptor or an enzyme.
VS is one of the numerous emerging strategies pharmaceutical companies are exploring to streamline their drug discovery processes. Over recent years, VS has demonstrated its efficacy as a strategy for effectively identifying bioactive molecules and presents the pharmaceutical industry with the potential to drastically speed up the drug discovery phase.
There are two main strategies implemented by VS, ligand-based screening techniques and structure-based screening techniques.
The compact Ziath DataPaq™ Express offers a space-saving way to integrate a fast full-rack scanner onto a liquid handling robot. The uniquely low form factor of the DataPaq™ Express allows liquid handling robots easy gripper access enabling simple pick up and dispensing from 2D racks and tubes on top of the scanner. Offering rapid image scanning and decoding in just two seconds, the camera based DataPaq™ Express will also help improve your robotic workflow.
Cyrogen Pharmed Limited. has set up its operation to deal with healthcare supply needs from local project level to national scale tenders, supplying various well-known brands of generic, pharmaceuticals, medical and consumable products.
© 2021 Copyright – All rights reserved by Cyrogen Pharmed Limited.
